The potential of targeted radiotherapies is undeniable, with the space growing year-on-year. As more drugs enter the clinic, collaboration between all the players involved in supply, development, manufacturing, transporting, administration and everything in between is vital. The promise is there, but to avoid being relegated to a treatment for a very niche indication, it’s time the space expanded.
We’re seeing an exciting shift towards testing on newer indications, such as ovarian cancers and brain tumors, as well as experimentation with drug design – seeing a variety of radioisotopes, linkers, and precursors being used. There is so much to explore across discovery and translational to clinical readouts. However, from the difficulties faced during the roll out of Pluvicto over the last year, serious discussion needs to happen on how to address late-stage challenges with supply and other logistics.
This why the 2nd Annual Targeted Radiopharmaceutical Summit US is retuning as the leading platform devoted to bring expert field leaders from the likes of PLUS Therapeutics, Fusion Pharmaceuticals, AstraZeneca and more to analyze the most recent advances of the last year and the potential of the targeted Radiopharmaceuticals field.
What You Can Expect:
Hear from the leading TRP developers: Clarity Pharmaceuticals, Mariana Oncology, Actinium Pharmaceuticals, PLUS Therapeutics to get an insight into how they are tackling development, supply and regulatory challenges
Connect with all the key stakeholders in the targeted radiopharmaceuticals space such as TRP developers, radioisotope suppliers, neurooncologists, contract manufacturers & precursor manufacturers
Review clinical progress for a variety of isotopes including 177-Lut, 212-Pb, 67-Cu, and 225-Act, for a thorough understanding of where the space is seeing success with the likes of Rayze Bio, OranoMed & more
Learn how to optimize targeted radionuclide therapy clinical trial design to ensure success through to IND approval
Explore applications beyond prostate cancers such as breast, neuroendocrine and lung cancers, to see how the space moves beyond being relegated to a niche therapeutic